Filgueira de Azevedo Walter, Canduri Fernanda, Simões de Oliveira Jaim, Basso Luiz Augusto, Palma Mário Sérgio, Pereira José Henrique, Santos Diógenes Santiago
Departamento de Física, UNESP, São José do Rio Preto, SP 15054-000, Brazil
Biochem Biophys Res Commun. 2002 Jul 5;295(1):142-8. doi: 10.1016/S0006-291X(02)00632-0.
Tuberculosis (TB) resurged in the late 1980s and now kills approximately 3 million people a year. The reemergence of tuberculosis as a public health threat has created a need to develop new anti-mycobacterial agents. The shikimate pathway is an attractive target for herbicides and anti-microbial agents development because it is essential in algae, higher plants, bacteria, and fungi, but absent from mammals. Homologs to enzymes in the shikimate pathway have been identified in the genome sequence of Mycobacterium tuberculosis. Among them, the shikimate kinase I encoding gene (aroK) was proposed to be present by sequence homology. Accordingly, to pave the way for structural and functional efforts towards anti-mycobacterial agents development, here we describe the molecular modeling of M. tuberculosis shikimate kinase that should provide a structural framework on which the design of specific inhibitors may be based.
结核病在20世纪80年代后期卷土重来,目前每年导致约300万人死亡。结核病作为一种公共卫生威胁的再度出现,引发了开发新型抗分枝杆菌药物的需求。莽草酸途径是除草剂和抗菌剂开发的一个有吸引力的靶点,因为它在藻类、高等植物、细菌和真菌中至关重要,但在哺乳动物中不存在。在结核分枝杆菌的基因组序列中已鉴定出莽草酸途径中酶的同源物。其中,通过序列同源性推测存在编码莽草酸激酶I的基因(aroK)。因此,为了为抗分枝杆菌药物开发的结构和功能研究铺平道路,我们在此描述结核分枝杆菌莽草酸激酶的分子建模,这应该能提供一个可基于其设计特异性抑制剂的结构框架。